GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2cureX AB (OSTO:2CUREX) » Definitions » EV-to-FCF

2cureX AB (OSTO:2CUREX) EV-to-FCF : 0.40 (As of May. 17, 2024)


View and export this data going back to 2017. Start your Free Trial

What is 2cureX AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, 2cureX AB's Enterprise Value is kr-11.93 Mil. 2cureX AB's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 was kr-29.83 Mil. Therefore, 2cureX AB's EV-to-FCF for today is 0.40.

The historical rank and industry rank for 2cureX AB's EV-to-FCF or its related term are showing as below:

OSTO:2CUREX' s EV-to-FCF Range Over the Past 10 Years
Min: -16.26   Med: 51.28   Max: 117.92
Current: 0.44

During the past 8 years, the highest EV-to-FCF of 2cureX AB was 117.92. The lowest was -16.26. And the median was 51.28.

OSTO:2CUREX's EV-to-FCF is ranked better than
76.38% of 381 companies
in the Biotechnology industry
Industry Median: 7.68 vs OSTO:2CUREX: 0.44

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-17), 2cureX AB's stock price is kr0.351. 2cureX AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was kr-1.874. Therefore, 2cureX AB's PE Ratio for today is At Loss.


2cureX AB EV-to-FCF Historical Data

The historical data trend for 2cureX AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2cureX AB EV-to-FCF Chart

2cureX AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-FCF
Get a 7-Day Free Trial -2,648.97 -17.14 -15.48 -11.95 -3.46

2cureX AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.58 -3.46 -2.74 -1.54 -1.31

Competitive Comparison of 2cureX AB's EV-to-FCF

For the Biotechnology subindustry, 2cureX AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


2cureX AB's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 2cureX AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where 2cureX AB's EV-to-FCF falls into.



2cureX AB EV-to-FCF Calculation

2cureX AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-11.925/-29.827
=0.40

2cureX AB's current Enterprise Value is kr-11.93 Mil.
2cureX AB's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-29.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


2cureX AB  (OSTO:2CUREX) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

2cureX AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.351/-1.874
=At Loss

2cureX AB's share price for today is kr0.351.
2cureX AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.874.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


2cureX AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of 2cureX AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


2cureX AB (OSTO:2CUREX) Business Description

Traded in Other Exchanges
Address
Fruebjergvej 3, Copenhagen, DNK, DK-2100
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.

2cureX AB (OSTO:2CUREX) Headlines

No Headlines